{"relation": [["", "Voriconazole, 200 BID (EM)", "Atazanavir/Ritonavir, 300/100 QD (EM)", "Atazanavir/Ritonavir, 300/100mgQD + Voriconazole, 200mgBID(EM)", "Voriconazole, 50 mg BID (PM)", "Atanazivir/Ritonavir, 300/100 QD + Voriconazole, 50 BID (PM)", "Atazanavir/Ritonavir, 300/100 QD (PM)"], ["Description", "Participants with functional CYP2C19 alleles (EM) received voriconazole, 400 mg, twice daily (BID) on Day 1, then 200 mg BID on Days 2 and 3. Voriconazole dose was given at least 1 hour after a meal.", "EM participants received atazanavir/ritonavir, 300/100 mg once daily (QD), on Days 11 through 20. Atazanavir/ritonavir dose was administered in the morning within 5 minutes of completing a light meal.", "EM participants received atazanavir/ritonavir, 300/100 mg QD, plus voriconazole, 400 mg BID on Day 21 then 200 mg BID on Days 22-30. Atazanavir/ritonavir dose was administered in the morning within 5 minutes of completing a light meal, and 1 hour before voriconazole morning dose.", "Participants who were poor metabolizers of CYP2C19 (PM)received voriconazole, 100 mg BID, on Day 1 then 50 mg BID on Days 2 and 3. Voriconazole dose was given at least 1 hour after a meal.", "PM participants received atazanavir/ritonavir, 300/100 mg QD, plus voriconazole, 100 mg BID, on Day 21, then 50 mg BID on Days 22-30.", "PM participants received atazanavir/ritonavir, 300/100 mg QD, on Days 11 through 20. Atazanavir/ritonavir dose was administered in the morning within 5 minutes of completing a light meal."]], "pageTitle": "Drug Interactions Between Voriconazole and Atazanavir Coadministered as Atazanavir/Ritonavir in Healthy Participants - Study Results - ClinicalTrials.gov", "title": "", "url": "https://clinicaltrials.gov/ct2/show/results/NCT00833482?sect=Xd0156&view=results", "hasHeader": true, "headerPosition": "MIXED", "tableType": "RELATION", "tableNum": 3, "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438044271733.81/warc/CC-MAIN-20150728004431-00325-ip-10-236-191-2.ec2.internal.warc.gz", "recordEndOffset": 874278906, "recordOffset": 874262512, "tableOrientation": "HORIZONTAL", "textBeforeTable": "Reporting Groups A total of 185 participants were enrolled in the study, and 153 were not treated, because they no longer met study criteria, withdrew consent, or were alternate participants who were no longer needed. The remaining 32 participants received treatment. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details No text entered. Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Drug: Voriconazole Drug: Atazanavir Drug: Ritonavir Interventions: Human Immunodeficiency Virus Type 1 (HIV-1) HIV Infections Conditions: Allocation:\u00a0Non-Randomized; \u00a0 Endpoint\u00a0Classification:\u00a0Pharmacokinetics\u00a0Study; \u00a0 Intervention\u00a0Model:\u00a0Single\u00a0Group\u00a0Assignment; \u00a0 Masking:\u00a0Open\u00a0Label Study Design:", "textAfterTable": "Participant Flow for 3 periods Period 1: \u00a0 Days 1-3 \u00a0 \u00a0 Voriconazole, 200 BID (EM) \u00a0 \u00a0 Atazanavir/Ritonavir, 300/100 QD (EM) \u00a0 \u00a0 Atazanavir/Ritonavir, 300/100mgQD + Voriconazole, 200mgBID(EM) \u00a0 \u00a0 Voriconazole, 50 mg BID (PM) \u00a0 \u00a0 Atanazivir/Ritonavir, 300/100 QD + Voriconazole, 50 BID (PM) \u00a0 \u00a0 Atazanavir/Ritonavir, 300/100 QD (PM) \u00a0 STARTED \u00a0 \u00a0 24 [1] \u00a0 0 [1] \u00a0 0 \u00a0 \u00a0 8 \u00a0 \u00a0 0 \u00a0 \u00a0 0 \u00a0 COMPLETED \u00a0 \u00a0 24 \u00a0 \u00a0 0 \u00a0 \u00a0 0 \u00a0 \u00a0 8 \u00a0 \u00a0 0 \u00a0 \u00a0 0 \u00a0", "hasKeyColumn": false, "keyColumnIndex": -1, "headerRowIndex": 0}